<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00424203</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000523419</org_study_id>
    <secondary_id>FRE-FNCLCC-GERICO-06-0502</secondary_id>
    <secondary_id>EU-20667</secondary_id>
    <secondary_id>EUDRACT-2005-000069-20</secondary_id>
    <nct_id>NCT00424203</nct_id>
  </id_info>
  <brief_title>Doxorubicin and Cyclophosphamide in Treating Older Women With Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery</brief_title>
  <official_title>Multicenter Pilot Clinical Study of Adjuvant Chemotherapy for Subjects Over 70 Years: Impact on the Independence and Quality of Life of the Administration of Anthracycline-Based Chemotherapy in Adjuvant Setting for Patients Presenting With Immediately Operable Breast Cancer, Hormone Receptor Negative (RH-), and Lymph Node Positive (pN+) or pN0 But of Scarff-Bloom-Richardson* Grade III and ≥ 2cm [GERICO]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as doxorubicin and cyclophosphamide, work in
      different ways to stop the growth of tumor cells, either by killing the cells or by stopping
      them from dividing. Giving combination chemotherapy after surgery may kill any tumor cells
      that remain after surgery.

      PURPOSE: This phase II trial is studying how well giving doxorubicin together with
      cyclophosphamide works in treating older women with stage I , stage II, or stage III breast
      cancer that has been removed by surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the independence of older women with resected stage I, II, or III breast
           cancer treated with adjuvant doxorubicin hydrochloride and cyclophosphamide.

      Secondary

        -  Determine the impact of this regimen on other aspects of the patient's life, utilizing
           the Comprehensive Geriatric Assessment, the Mini-Nutritional Assessment, the Folstein
           Mini-Mental State Exam, the Geriatric Depression Scale, and the Cumulative Illness
           Rating Scale-Geriatrics.

        -  Determine the quality of life of patients treated with this regimen.

        -  Determine the acceptability of this regimen in these patients.

        -  Determine the toxicity of this regimen, in terms of cardiac issues and anemia, in these
           patients.

        -  Determine recurrence-free survival, event-free survival, and overall survival of
           patients treated with this regimen.

      OUTLINE: This is a pilot, nonrandomized, multicenter study.

      Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1. Treatment
      repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable
      toxicity.

      Patients complete questionnaires at baseline and after completion of chemotherapy.
      Questionnaires include the Comprehensive Geriatric Assessment, the Mini-Nutritional
      Assessment (malnutrition), the Folstein Mini-Mental State Exam (cognitive function), the
      Geriatric Depression Scale (depression), the Cumulative Illness Rating Scale - Geriatrics
      (comorbidities), and the EORTC Quality of Life Questionnaire Core 30 (quality of life).

      After completion of study therapy, patients are followed every 3 months for 4 years.

      PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients maintaining their independence as assessed by Activities of Daily Living (ADL) score on 6 items after the fourth course of chemotherapy</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact of adjuvant chemotherapy on ADL score, quality of life, treatment acceptability, toxicity, and survival (recurrence-free, progression-free, and overall survival)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Cognitive/Functional Effects</condition>
  <condition>Depression</condition>
  <condition>Malnutrition</condition>
  <condition>Psychosocial Effects of Cancer and Its Treatment</condition>
  <arm_group>
    <arm_group_label>Myocet, Endoxan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AC regimen</intervention_name>
    <arm_group_label>Myocet, Endoxan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <arm_group_label>Myocet, Endoxan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <arm_group_label>Myocet, Endoxan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
    <arm_group_label>Myocet, Endoxan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cognitive assessment</intervention_name>
    <arm_group_label>Myocet, Endoxan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>management of therapy complications</intervention_name>
    <arm_group_label>Myocet, Endoxan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>psychosocial assessment and care</intervention_name>
    <arm_group_label>Myocet, Endoxan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
    <arm_group_label>Myocet, Endoxan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed invasive adenocarcinoma of the breast

               -  Stage I, II or III disease

                    -  pN+ or pN0 with grade III disease (tumor size ≥ 2 cm)

                    -  No metastatic disease

          -  Must have undergone prior conservative or radical surgery that included axillary lymph
             node or sentinel node dissection

               -  No residual tumor

               -  Negative margins

          -  Hormone receptor status:

               -  Estrogen receptor and progesterone receptor negative

        PATIENT CHARACTERISTICS:

          -  Female

          -  Postmenopausal

          -  Absolute neutrophil count &gt; 1,500/mm³

          -  Platelet count &gt; 100,000/mm³

          -  Hemoglobin &gt; 10 g/dL

          -  Alkaline phosphatase &lt; 2.5 times upper limit of normal (ULN)

          -  Bilirubin &lt; 1.25 times ULN

          -  AST and ALT &lt; 2.5 times ULN

          -  Creatinine clearance ≥ 40 mL/min

          -  No contraindication to receiving anthracyclines or alkalizing agents

          -  FEV normal

          -  Activities of Daily Living (ADL) score ≥ 5

               -  No decrease of ≥ 1 point within the past 3 months

          -  None of the following at baseline:

               -  Cognitive deficiency (Folstein Mini-Mental State &lt; 25)

               -  Severe depression (Geriatric Depression Scale ≥ 20)

               -  Severe malnutrition (Mini-Nutritional Assessment ≤ 17)

          -  No other serious comorbid condition (Cumulative Illness Rating Scale - Geriatrics
             grade 3-4), including any of the following:

               -  Cardiac insufficiency

               -  Unstable angina

               -  Myocardiopathy

               -  Myocardial infarction within the past year

               -  Uncontrolled hypertension

               -  Uncontrolled high-risk arrhythmia

               -  Severe medullary insufficiency

               -  Neurological or psychological condition that would preclude study consent

               -  Uncontrolled or active infection

               -  Severe urinary tract infection

               -  Preexisting hematuria

               -  Active ulcer

               -  Uncontrolled diabetes

          -  No other cancer within the past 5 years except for basal cell skin cancer or carcinoma
             in situ of the cervix

          -  No familial, geographical, social, or psychological condition that would preclude
             study participation

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  At least 60 days since prior therapeutic surgery

          -  At least 4 weeks since prior investigational drugs
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>E. G. C. Brain, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Curie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49036</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Sainte Catherine</name>
      <address>
        <city>Avignon</city>
        <zip>84082</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Perpetuel Secours</name>
      <address>
        <city>Levallois</city>
        <zip>92309</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional Rene Gauducheau</name>
      <address>
        <city>Nantes-Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Europeen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie Hopital</name>
      <address>
        <city>Paris</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <zip>51056</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugene Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Rene Huguenin</name>
      <address>
        <city>Saint Cloud</city>
        <zip>92211</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H. Senlis</name>
      <address>
        <city>Senlis</city>
        <zip>60309</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Vandoeuvre-les-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2007</study_first_submitted>
  <study_first_submitted_qc>January 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2007</study_first_posted>
  <last_update_submitted>September 2, 2013</last_update_submitted>
  <last_update_submitted_qc>September 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cognitive/functional effects</keyword>
  <keyword>depression</keyword>
  <keyword>malnutrition</keyword>
  <keyword>psychosocial effects of cancer and its treatment</keyword>
  <keyword>stage IA breast cancer</keyword>
  <keyword>stage IB breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>estrogen receptor-negative breast cancer</keyword>
  <keyword>progesterone receptor-negative breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Malnutrition</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

